多发性骨转移癌骨痛的内照射治疗
游金辉
【期刊名称】《川北医学院学报》
【年(卷),期】2007(022)001
【摘要】89SrCl2、153Sm-EDTMP、188Re-HEDP以及与它们相关的联合治疗方法对多发性骨转移瘤患者的姑息止痛效果为70%-90%以上,其疗效与病理类型密切相关;153Sm-EDTMP的骨髓抑制作用较89SrCl2严重,临床可首选188Re-HEDP 或89SrCl2.
【总页数】4页(P60-63)
【作者】游金辉
【作者单位】川北医学院附属医院核医学科,四川,南充,637000
【正文语种】中文
【中图分类】R815
【相关文献】
1.89Sr、153Sm内照射治疗骨转移癌引起骨痛的剂量研究 [J], 张军宁;洪承皎;朱寿彭
2.89SrCl2治疗多发性骨转移癌骨痛与ET、CGRP、TXB2、6-K-PGF1a的关系[J], 孙文伟;魏丽琴;谭平;马庆杰
3.89SrCl2内照射治疗多发性骨髓瘤所致骨痛的临床疗效研究 [J], 吴楠;胡龙虎;周晋;杨慧芬
4.云克联合153Sm-EDTMP治疗多发性骨转移癌骨痛49例疗效分析及护理 [J],
李琼珍;周爱清;陈志军
5.^(153)Sm-EDTMP治疗多发性骨转移癌骨痛89例临床护理 [J], 李琼珍;周爱清;陈志军
因版权原因，仅展示原文概要，查看原文内容请购买。
SRS与SRT配合全脑放射治疗脑转移瘤疗效观察
龙志雄;孙劲松;陈桂明;蔡鹏;杨士勇;彭云武;邓峥嵘
【期刊名称】《中国误诊学杂志》
【年(卷),期】2003(3)12
【总页数】2页(P1827-1828)
【关键词】脑肿瘤/放射疗法;脑肿瘤转移/放射疗法
【作者】龙志雄;孙劲松;陈桂明;蔡鹏;杨士勇;彭云武;邓峥嵘
【作者单位】湖北省荆门市第二人民医院肿瘤科
【正文语种】中文
【中图分类】R739.41
【相关文献】
1.立体定向放射治疗配合全脑照射治疗脑转移瘤疗效分析 [J], 朱苏元;陈庆森;方建平;徐广
2.分次立体定向放疗联合短程全脑放射治疗脑转移瘤的临床疗效观察 [J], 曹新桥;王兵;田恒;石庆芳
3.脑转移瘤全脑照射配合分次立体定向放射治疗疗效分析 [J], 宋金丽
4.X射线立体定向放射治疗配合全脑照射治疗脑转移瘤疗效分析 [J], 岳养军;陈菊梅;魏世华;田种泽
5.25例肺癌脑转移立体定向放射治疗配合全脑放疗的近期疗效观察 [J], 马建萍;折虹;郭庆敏;海平
因版权原因，仅展示原文概要，查看原文内容请购买。
89Srcl2联合唑来膦酸治疗肺癌骨转移的Meta分析马平川】，程光华2,葛俊亮2,杨继文2,陈晓磊2（皖南医学院1.研究生学院;2.附属弋矶山医院核医学科，安徽芜湖241000）摘要：目的系统性评价89Srcl2(氯化锶)联合唑来膦酸治疗肺癌骨转移的临床效果及毒副反应。
方法计算机网络检索中英文医学数据库(Pubmed、Web of science、Ovid、EMbase、Cochrane library、中国知网、万方数据库、维普数据库、中国生物医学文献数据库)，筛选89Srcl2联合唑来膦酸治疗肺癌骨转移患者的随机对照实验(randomized controlled trials,RCT)，搜索起止时间为建库至2020年4月30日，对联合用药组及单药组的骨痛缓解率、骨转移灶控制率、不良反应发生率、首次骨相关事件(SREs)及总生存期(OS)，利用RevMan5.3软件进行Meta分析。
结果纳入了7篇文献共555名患者，联合组的骨痛缓解率既优于单用唑来膦酸组(P=0.03)又优于单用89Srcl2组(P=0.04)，骨转移灶控制率既要优于唑来膦酸组(P=0.0003)，也要优于89Srcl2组(P=0.006)，联合组较单用89Srcl2组延长了首次发生SREs的时间(P=0.008)及1年总生存期(P=0.0036)。
联合组在毒副反应发生率方面与唑来膦酸组(P=0.79)及89Srcl2组(P=0.97)之间无显著统计学差异。
结论89Srcl2联合唑来膦酸治疗肺癌骨转移的近期及远期疗效优于单药组，毒副反应相对无增加,联合用药可以作为肺癌骨转移患者的优先治疗方案。
关键词：89Sr；肺癌；唑来膦酸;荟萃分析中图分类号：R734.2文献标识码：A文章编号：1001-7550(2020)06-0021-07Meta-analysis of the efficacy and safety of89Srcl2combined with zoledronic acid in the treatment of lung cancer with bone metastasisMA Ping-chuan et al(Graduate school of wannan medical college，Wuhu241000,China)Abstract:Objective To systematically evaluate the clinical effects and side effects of89Srcl? (Strontium chloride)combined with zoledronic acid in the treatment of bone metastasis of lung cancer.Methods Computer network was used to retrieve both English and Chinese medical databases(Pubmed, Web of science,Ovid,EMbase,the Cochrane library,CNKI,Wanfang database, Weipu database,CBM) ,screening89Srcl2combined zoledronic acid treatment of lung cancer patients with bone metastases of randomized controlled trials(RCT),starting and ending time search for libraries to April30,2020.RevMan5.3was used for Meta-analysis of bone pain relief rate,bone metastasis control rate,incidence of adverse reactions,first bone-related events(SREs),and overall survival(OS)in the combined and single drug groups.Results The included7articles were a total of555patients,and the remission rate of bone pain in the combined group was better than that of the zoledronic acid group alone(P=0.03)and that of the89Srcl2group alone(P=0.04), bone metastases control was superior to both zoledronic acid group(P=0.0003),and it was better than89srcl2group(P=0.006),the joint group extended the SREs first took place in the89srcl2alone group( P=0.008),and1year time overall survival(P=0.0036). There was no statistically significant difference in the incidence of adverse reactions between the combined group and the zoledronic acid group(P=0.79)and the89Srcl2group(P=0.97).Conclusion The short-term and long-term efficacy of89Srcl2combined with zoledronic acid in the treatment of bone metastasis of lung cancer is better than that of the single drug group,and the side effects are relatively not increased.Key words:89Sr；lung cancer；Zoledronic Acid；Meta-analysis在过去的几年中,肺癌的研究领域取得了显著的进展，但肺癌仍然是全世界癌症致死的重要原因［1］。
局部晚期喉癌和下咽癌容积旋转调强与螺旋断层放疗的剂量学研究解传滨;徐寿平;葛瑞刚;徐伟;丛小虎;鞠忠建;巩汉顺;蔡博宁【摘要】目的：比较局部晚期喉癌和下咽癌RapidArc（ RA）容积旋转调强放疗与螺旋断层放疗（ HT）剂量学差异，探讨2种调强技术特点及剂量学优势。
方法选取10例喉癌（4例）和下咽癌（6例）术后患者，分别设计RA、HT两组治疗计划，比较靶区及危及器官剂量分布、剂量体积直方图（ DVH）等指标情况，并对机器跳数（ MU）与出束时间予以评估。
结果两者均实现了95％以上靶体积的剂量覆盖，并体现出类似的剂量均匀性。
RA组腮腺、口腔V10较HT组分别降低了9．6％、13．6％（P＝0．03／0．00），而HT组V40却降低了13．4％、13．7％（P＝0．00／0．21）。
在减少正常组织（NT）受量上RA更具优势，而HT实现了对脊髓更好的避让。
RA／HT两组计划的平均机器跳数和出束时间分别为820 MU／5367 MU、377 s／150 s。
结论两种旋转调强技术均能较好地实现喉癌和下咽癌照射，且RA在减少低剂量照射及计划实施效率上更具优势。
%Objective To compare the dosimetric characteristics of helical tomotherapy ( HT) and RapidArc ( RA) therapy for laryngeal and hypopharyngeal carcinoma.Methods 10 patients with post-operative laryngeal or hypopharyngeal carci-noma were enrolled in this study.RA plans and HT plans were created for each patient and according to dose-volume histogram ( DVH) analysis in terms of PTV homogeneity and conformity indices ( HI and CI) as well as OARs dose and volume parameters were compared.Additionally,the cumulative monitor unit (MUs) and treatment delivery times of the different technologies wereanalyzed.Results The 2 techniques could well achieve the target coverage (95%) and showed a similar dose uniformity.RA showed better in the low dose distribution of the organs such as parotids and oral,but the HT plans have a visible advantage over the RA plans in the high dose,the V40 of parotids and oral were reduced by 13.4%,13.7%(P=0.00/0.21).The MU and treat-ment delivery time of RA and HT were 820 MU/5 367 MU,377 s/150 s.Conclusion The 2 kinds of treatment plans can provide good dose distribution.And RA seems to be obviously better in low dose distribution and the delivery efficiency.【期刊名称】《实用癌症杂志》【年(卷),期】2016(000)001【总页数】4页(P120-123)【关键词】喉癌;下咽癌;快速容积旋转调强;螺旋断层放射治疗;剂量学【作者】解传滨;徐寿平;葛瑞刚;徐伟;丛小虎;鞠忠建;巩汉顺;蔡博宁【作者单位】100853 解放军总医院;100853 解放军总医院;100853 解放军总医院;100853 解放军总医院;100853 解放军总医院;100853 解放军总医院;100853 解放军总医院;100853 解放军总医院【正文语种】中文【中图分类】R739.65近年来，旋转调强放疗(intensity-modulted arc radiotherapy,IMAT)普遍应用于临床，Vanrtti等[1]在对IMAT与IMRT计划的比较研究中肯定了双弧IMAT在下咽部位肿瘤中的优势。
